The ZBTB43 antibody targets the ZBTB43 protein, a member of the zinc finger and BTB domain-containing (ZBTB) family of transcription factors. ZBTB43. also known as ZNF307. is implicated in transcriptional regulation, chromatin remodeling, and epigenetic modulation. It contains an N-terminal BTB domain, which mediates protein-protein interactions, and C-terminal zinc finger motifs that facilitate DNA binding. ZBTB43 is notably involved in 5-hydroxymethylcytosine (5hmC) recognition, a DNA modification associated with active gene regulation and tumor suppression. Dysregulation of ZBTB43 has been linked to cancer, particularly colorectal cancer, where its expression is often downregulated due to promoter hypermethylation, suggesting a potential role as a tumor suppressor or biomarker. The ZBTB43 antibody is widely used in research to study DNA methylation dynamics, chromatin accessibility, and gene silencing mechanisms in both normal and pathological contexts. It is critical for techniques like ChIP-seq, immunohistochemistry, and Western blotting to explore ZBTB43's interaction with DNA hydroxymethylation sites and its functional impact on cellular differentiation, apoptosis, and oncogenesis. Studies using this antibody contribute to understanding epigenetic dysregulation in diseases and developing targeted therapies.